Graft Vs Host Disease Clinical Trials 2023

What are the top hospitals conducting graft vs host disease research?

When it comes to cutting-edge clinical trials in the complex realm of graft vs host disease (GVHD), several hospitals are leading the way. In Boston, both Dana-Farber Cancer Institute and Massachusetts General Hospital have dedicated themselves to understanding and treating this challenging condition. Dana Farber currently has nine active GVHD trials underway, building upon their impressive history of 23 completed studies since their inaugural trial in 2001. Not far behind is Dana-Farber Cancer Institute with eight ongoing GVHD trials and a significant track record of 35 previous investigations, dating back to 2000. Meanwhile, over at Massachusetts General Hospital, researchers are actively engaged in eight GVHD trials while having conducted an admirable total of 29 such studies since recording their first trial in 2001.

Venturing outside the city limits, we find another prominent institution making strides in the field - The National Institutes of Health Clinical Center located in Bethesda. This renowned center currently has seven active clinical trials focused on GVHD and boasts a respectable history of fourteen previously conducted investigations that date all the way back to 1996 when they recorded their initial study on this subject.

Lastly but certainly not least, we turn our attention towards the West Coast where Fred Hutchinson Cancer Research Center stands as a beacon for innovation and progress against GVHD. Situated amidst Seattle's vibrant medical community, this prestigious research center currently features seven active clinical trials tackling graft vs host disease head-on while contributing significantly through an astonishing fifty-one completed studies since recording its first ground-breaking trial back in1986.

These hospitals' unwavering commitment to unraveling the complexities surrounding graft vs host disease demonstrates how dedication and collaboration fuel scientific advancement. Through these pioneering efforts carried out across various locations nationwide , hope continues to grow for patients affected by this challenging condition as breakthroughs inch closer within reach

Which are the best cities for graft vs host disease clinical trials?

When it comes to graft vs host disease clinical trials, several cities emerge as prominent hubs for research and development. Boston, Massachusetts leads the way with 41 active trials investigating treatments like Abatacept, Interleukin-2, and Cohort A: Belumosudil + Standard of Care Medications. New york City follows closely behind with 23 ongoing studies exploring therapies such as Ibrutinib, Alpha-1 antitrypsin (AAT), and GDC-8264. Duarte, California also plays a significant role in this field with 21 active trials focusing on Ibrutinib, Belumosudil (KD025), Axatilimab among other interventions. Additionally, Seattle, Washington and Atlanta Georgia have notable contributions to graft vs host disease clinical trials with 16 and 15 active studies respectively researching innovative treatments like Alpha-1 antitrypsin (AAT) and Abatacept. These cities offer individuals affected by graft vs host disease access to cutting-edge clinical trials that pave the way for better care options and improved patient outcomes.

Which are the top treatments for graft vs host disease being explored in clinical trials?

Graft vs host disease, a complex condition, is the focus of extensive research in ongoing clinical trials. Among the top treatments being explored are:

• Ibrutinib: Showcasing its potential with five active trials and nine all-time graft vs host disease studies since 2013.
• Abatacept: Proving its worth in three ongoing trials and seven previous graft vs host disease investigations which began in 2013.
• Cyclophosphamide: Demonstrating promise through three active and 30 all-time graft vs host disease trials dating back to 2007.
• Ruxolitinib: Making strides with three active and a total of fourteen past graft vs host disease studies initiated from 2016 onwards.

These innovative treatment options hold immense hope for patients battling this challenging disorder.

What are the most recent clinical trials for graft vs host disease?

Exciting advancements are underway in the realm of graft vs host disease, with recent clinical trials offering hope for improved treatment strategies. One notable trial focuses on CD34+ Peripheral Blood Progenitor Cell (PBSC) Transplant combined with a Busulfan/Melphalan/Fludarabine Regimen. This Phase 2 study brings potential benefits to individuals grappling with graft vs host disease by exploring novel transplantation methods. Another trial investigates prophylaxis techniques specifically tailored to mitigate the risk of graft vs host disease development, showing promise as a preventive measure. Additionally, steroid therapy and corticosteroid treatments have emerged as candidates for managing graft vs host disease symptoms based on encouraging results from Phase 1 and Phase 2 trials. With these innovative approaches emerging, there is renewed optimism for better outcomes in the battle against graft vs host disease.

What graft vs host disease clinical trials were recently completed?

Recent completion of numerous clinical trials for graft vs host disease brings hope and progress in the battle against this challenging condition. Notable studies include a December 2020 trial sponsored by the University of California, San Francisco, focusing on dexamethasone 0.5mg/5ml solution in Mucolox™. Genentech, Inc., completed their Efmarodocokin Alfa trial in November 2020. Further advancements were made with Washington University School of Medicine's Baricitinib trial concluding in April 2020 and Regimmune Corporation's RGI-2001 study finishing in November 2019. These milestones underline ongoing efforts to enhance treatment options for patients grappling with graft vs host disease.